Agbelo News为您提供股票配资的相关知识，让您深度了解配资行业，配资策略是专业的配资行业大数据平台，提供专业的配资新闻，配资知识，股票入门等多维度，全方位的资讯信息服务。
Pursuit Minerals (PUR) has returned multiple high-grade results from rock chip sampling at its Commando gold project, around 38 kilometres north of Kalgoorlie, WA.
Pursuit Minerals (ASX:PUR) returns multiple high-grade gold sample results at Commando, WA -Agbelo News 更多配资
Tempus Resources (TMR) has hit gold in the first holes drilled into the No. 9 vein at its Elizabeth project in Southern British Columbia, Canada.
Tempus Resources (ASX:TMR) sees more gold at Elizabeth project, Canada -Agbelo News 更多配资
Hydrix (HYD) has received approval from the Health Services Authority of Singapore (HSA) to market and distribute the Guardian device in the country.
Hydrix (ASX:HYD) receives Singapore HSA approval for Guardian device -Agbelo News 更多配资
Aerial mapping company Nearmap (NEA) has received a $1.055 billion takeover bid from US-based software investment firm Thoma Bravo.
Nearmap (ASX:NEA) receives $1b takeover bid from US investment firm -Agbelo News 更多配资
Blaze Minerals (BLZ) has seen early success at its Earaheedy Basin project in Western Australia after beginning drilling in late July.
Blaze Minerals (ASX:BLZ) sees early drill success at Earaheedy, WA -Agbelo News 更多配资
The ACCC has not opposed on the deal the MyDeal (MYD) takeover by Woolworths (WOW).
ACCC approves Woolworths (ASX:WOW) and MyDeal (ASX:MYD) acquisition -Agbelo News 更多配资
E-commerce enabler, eCargo (ECG) has divested its digital commerce consultancy, Amblique in a management buyout for US$5 million (A$7.03 million).
eCargo (ASX:ECG) sells Amblique to focus on Asian market -Agbelo News 更多配资
Baby Bunting (BBN) has surpassed half a billion dollars in sales for the first time.
Baby Bunting (ASX:BBN) surpasses $500m sales for the first time -Agbelo News 更多配资
Calidus Resources (CAI) has received firm commitments to raise $20 million via a share placement.
Calidus Resources (ASX:CAI) eyes $20m to accelerate lithium & gold exploration -Agbelo News 更多配资
Cynata Therapeutics (CYP) has completed a strategic review of its clinical development pipeline to maximise commercial opportunities.
Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review -Agbelo News 更多配资